Progesterone Management in Early Pregnancy Outcomes

Progesterone is a pivotal hormone for establishing and maintaining early gestation, exerting its effects through endometrial differentiation, immunomodulation and support of the embryo implantation process. Adequate progesterone production by the corpus luteum during the luteal phase and its subsequent sustentation via the luteal–placental shift are critical to minimise the risk of threatened miscarriage and spontaneous abortion. Progesterone supplementation, in forms ranging from oral progestogens to vaginal formulations, has become a cornerstone of clinical management for women presenting with early pregnancy complications. Recent advances have focused on optimising delivery systems to improve local bioavailability, defining serum thresholds that accurately stratify miscarriage risk, and elucidating the dose-dependent immunological effects of progesterone on pro- and anti-inflammatory cytokines. These developments have global significance as they refine therapeutic strategies, reduce adverse outcomes and inform personalised care pathways for at-risk populations.

Research from Nature Portfolio

A large cross-sectional study established week-by-week normative values for serum progesterone during the first trimester in low-risk pregnancies, revealing an overall rising trend interrupted by a transient decline at gestational weeks 6–8 that corresponds to the luteal–placental shift. The analysis identified maternal factors such as age, body mass index and parity as significant determinants of progesterone levels and provided reference ranges that may underpin future efforts to define pathological thresholds associated with miscarriage risk.

Progesterone Management in Early Pregnancy Outcomes publication trend

The graph below shows the total number of articles in progesterone management in early pregnancy outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Threatened miscarriage: Vaginal bleeding in early pregnancy with a closed cervix, indicating potential risk of pregnancy loss.

Luteal–placental shift: Transition period when progesterone production transfers from the corpus luteum to the developing placenta, typically around gestational weeks 6–8.

Mucoadhesion: Property of a delivery system to adhere to mucosal epithelium, enhancing local drug retention and absorption.

Dydrogesterone: Synthetic progestogen structurally similar to natural progesterone, used orally to support early pregnancy.

References

1. In Vitro and Ex Vivo Evaluation of Novel Methacrylated Chitosan-PNIPAAm-Hyaluronic Acid Hydrogels Loaded with Progesterone for Applications in Vaginal Delivery. Polymers (2024).
2. Gestational age-specific normative values and determinants of serum progesterone through the first trimester of pregnancy. Scientific Reports (2021).
3. Baseline Levels of Serum Progesterone and the First Trimester Pregnancy Outcome in Women with Threatened Abortion: A Retrospective Cohort Study. BioMed Research International (2020).
4. Effects of Different Progesterone Doses on the Concentrations of Proinflammatory and Anti-inflammatory Cytokines in Pregnant Women With Threatened Abortion. Cureus (2021).